{"filing":{"accession_number":"0001668397-26-000034","cik":"0001668397","ticker":"MEDP","company_name":"Medpace Holdings, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-20","primary_document":"medp-20261020.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668397/000166839726000034/medp-20261020.htm"},"events":[{"id":36767,"run_id":33899,"accession_number":"0001668397-26-000034","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Medpace issued a press release on October 21, 2026 announcing third-quarter 2026 financial results, including revenue of $716.0 million (8.5% growth), GAAP net income of $137.5 million ($4.84 per diluted share), EBITDA of $172.1 million, and full-year 2026 guidance.","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41285,"accession_number":"0001668397-26-000034","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Medpace issued a press release on October 21, 2026 announcing financial results for the three and nine months ended September 30, 2026. The disclosure includes third-quarter revenue of $716.0 million (8.5% growth), GAAP net income of $137.5 million ($4.84 per diluted share), EBITDA of $172.1 million, and full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:14.770346+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":36768,"run_id":33899,"accession_number":"0001668397-26-000034","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Medpace terminated its $527.0 million share repurchase authorization and approved a new $1.0 billion share repurchase authorization through December 31, 2028, reflecting management's confidence in cash generation and capital deployment strategy.","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41286,"accession_number":"0001668397-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure announces termination of a $527.0 million repurchase authorization and approval of a new $1.0 billion share repurchase authorization through December 31, 2028. While share repurchases are a form of capital return to shareholders, this event is primarily a capital allocation decision and authorization rather than an actual distribution or return of capital. However, the material increase in authorization ($1.0 billion vs. $527.0 million remaining) and extension of the program through 2028 signal management's confidence in cash generation and capital deployment strategy, making it material to investors assessing capital allocation priorities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:14.770346+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41285,"accession_number":"0001668397-26-000034","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Medpace issued a press release on October 21, 2026 announcing financial results for the three and nine months ended September 30, 2026. The disclosure includes third-quarter revenue of $716.0 million (8.5% growth), GAAP net income of $137.5 million ($4.84 per diluted share), EBITDA of $172.1 million, and full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:14.770346+00:00","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-10-21"},{"id":41286,"accession_number":"0001668397-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 8.01 disclosure announces termination of a $527.0 million repurchase authorization and approval of a new $1.0 billion share repurchase authorization through December 31, 2028. While share repurchases are a form of capital return to shareholders, this event is primarily a capital allocation decision and authorization rather than an actual distribution or return of capital. However, the material increase in authorization ($1.0 billion vs. $527.0 million remaining) and extension of the program through 2028 signal management's confidence in cash generation and capital deployment strategy, making it material to investors assessing capital allocation priorities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:34:14.770346+00:00","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-10-21"}]}